These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. 4-hydroxy-5,6-dihydro-2H-pyran-2-ones.3. Bicyclic and hetero-aromatic ring systems as 3-position scaffolds to bind to S1' and S2' of the HIV-1 protease enzyme. Ellsworth EL; Domagala J; Prasad JV; Hagen S; Ferguson D; Holler T; Hupe D; Graham N; Nouhan C; Tummino PJ; Zeikus G; Lunney EA Bioorg Med Chem Lett; 1999 Jul; 9(14):2019-24. PubMed ID: 10450973 [TBL] [Abstract][Full Text] [Related]
8. Nonpeptidic HIV protease inhibitors: 4-hydroxy-pyran-2-one inhibitors with functional tethers to P1 phenyl ring to reach S3 pocket of the enzyme. Vara Prasad J; Tummino PJ; Ferguson D; Saunders J; Vander Roest S; McQuade TJ; Heldsinger A; Reyner EL; Stewart BH; Guttendorf RJ; Para KS; Lunney EA; Gracheck SJ; Domagala JM Biochem Biophys Res Commun; 1996 Apr; 221(3):815-20. PubMed ID: 8630044 [TBL] [Abstract][Full Text] [Related]
9. Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure. Romines KR; Watenpaugh KD; Howe WJ; Tomich PK; Lovasz KD; Morris JK; Janakiraman MN; Lynn JC; Horng MM; Chong KT J Med Chem; 1995 Oct; 38(22):4463-73. PubMed ID: 7473573 [TBL] [Abstract][Full Text] [Related]
10. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease. Sham HL; Zhao C; Stewart KD; Betebenner DA; Lin S; Park CH; Kong XP; Rosenbrook W; Herrin T; Madigan D; Vasavanonda S; Lyons N; Molla A; Saldivar A; Marsh KC; McDonald E; Wideburg NE; Denissen JF; Robins T; Kempf DJ; Plattner JJ; Norbeck DW J Med Chem; 1996 Jan; 39(2):392-7. PubMed ID: 8558507 [TBL] [Abstract][Full Text] [Related]
11. Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors. Thaisrivongs S; Watenpaugh KD; Howe WJ; Tomich PK; Dolak LA; Chong KT; Tomich CC; Tomasselli AG; Turner SR; Strohbach JW J Med Chem; 1995 Sep; 38(18):3624-37. PubMed ID: 7658450 [TBL] [Abstract][Full Text] [Related]
12. Structure-based design of achiral, nonpeptidic hydroxybenzamide as a novel P2/P2' replacement for the symmetry-based HIV protease inhibitors. Randad RS; Lubkowska L; Silva AM; Guerin DM; Gulnik SV; Yu B; Erickson JW Bioorg Med Chem; 1996 Sep; 4(9):1471-80. PubMed ID: 8894104 [TBL] [Abstract][Full Text] [Related]
13. A quantitative structure-activity relationship study on some sulfolanes and arylthiomethanes acting as HIV-1 protease inhibitors. Gupta SP; Babu MS; Sowmya S Bioorg Med Chem; 1998 Nov; 6(11):2185-92. PubMed ID: 9881109 [TBL] [Abstract][Full Text] [Related]
14. A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV. Yedidi RS; Garimella H; Aoki M; Aoki-Ogata H; Desai DV; Chang SB; Davis DA; Fyvie WS; Kaufman JD; Smith DW; Das D; Wingfield PT; Maeda K; Ghosh AK; Mitsuya H Antimicrob Agents Chemother; 2014 Jul; 58(7):3679-88. PubMed ID: 24752271 [TBL] [Abstract][Full Text] [Related]
15. Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'. Ax A; Schaal W; Vrang L; Samuelsson B; Hallberg A; Karlén A Bioorg Med Chem; 2005 Feb; 13(3):755-64. PubMed ID: 15653343 [TBL] [Abstract][Full Text] [Related]